Who is this relevant for?
- Pharmaceutical buyers sourcing shortage medicines
- Distributors monitoring sourcing opportunities
- Manufacturers evaluating UK market entry
Chiesi Group has agreed to acquire KalVista Pharmaceuticals for $1.9 billion. The deal adds KalVista's pipeline to Chiesi's existing rare disease portfolio. For pharma operators, the acquisition highlights ongoing consolidation in the rare disease sector. Buyers and distributors should monitor supply dynamics and product availability as integration unfolds.